Ascendis Pharma A/S

Historical 13F Holders

Symbol
ASND
CUSIP
04351P101
All holders as of
Q2 2026
Type
Equity
Class
SPONSORED ADR
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 04351P101 since 12/18/2024, newest first.

Filer % of Class Filed
Janus Henderson Group PLC 13G/A Amendment 9 6.0% 5/15/2026
Event 3/31/2026
Capital International Investors 13G/A Amendment 1 3.2% 5/14/2026
Event 3/31/2026
T. Rowe Price Investment Management, Inc. 13G/A Amendment 1 10.5% 5/7/2026
Event 4/30/2026
T. Rowe Price Investment Management, Inc. 13G 9.9% 5/7/2026
Event 3/31/2026
Westfield Capital Management Co LP 13G/A Amendment 4 8.5% 2/11/2026
Event 12/31/2025
Artisan Partners Limited Partnership 13G/A Amendment 6
5.2% 2/3/2026
Event 12/31/2025
T. Rowe Price Investment Management, Inc. 13G/A Amendment 2 4.8% 11/14/2025
Event 9/30/2025
Janus Henderson Group PLC 13G/A Amendment 8 7.8% 11/14/2025
Event 9/30/2025
T. Rowe Price Investment Management, Inc. 13G/A Amendment 1 6.4% 8/14/2025
Event 6/30/2025
Janus Henderson Group PLC 13G/A Amendment 7 8.0% 8/14/2025
Event 6/30/2025
Capital International Investors 13G 5.6% 8/13/2025
Event 6/30/2025
T. Rowe Price Investment Management, Inc. 13G 5.0% 5/14/2025
Event 3/31/2025
Janus Henderson Group PLC 13G/A Amendment 6 7.4% 5/14/2025
Event 3/31/2025
FMR LLC 13G/A Amendment 11
8.0% 5/12/2025
Event 3/31/2025
Janus Henderson Group PLC 13G/A Amendment 5 7.2% 2/14/2025
Event 12/31/2024
Westfield Capital Management Co LP 13G/A Amendment 3 9.2% 2/11/2025
Event 12/31/2024
Westfield Capital Management Co LP 13G/A Amendment 2 9.2% 2/10/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 1 2.60 k $592 k
2026 Q2 11 543 k $145 M
2026 Q1 293 54.7 M $12.5 B
2025 Q4 335 65.8 M $14.0 B
2025 Q3 306 68.8 M $12.7 B
2025 Q2 266 63.3 M $10.9 B
2025 Q1 262 65.6 M $10.2 B
2024 Q4 229 64.2 M $8.77 B
2024 Q3 242 63.1 M $9.32 B
2024 Q2 223 60.9 M $8.30 B
2024 Q1 214 61.1 M $9.24 B
2023 Q4 208 60.9 M $7.67 B
2023 Q3 178 60.3 M $5.64 B
2023 Q2 177 61.0 M $5.45 B
2023 Q1 183 61.0 M $6.54 B
2022 Q4 212 66.1 M $8.07 B
2022 Q3 206 70.6 M $7.29 B
2022 Q2 181 63.2 M $5.88 B
2022 Q1 201 62.1 M $7.28 B
2021 Q4 190 58.4 M $7.86 B
2021 Q3 186 58.0 M $9.25 B
2021 Q2 189 55.0 M $7.24 B
2021 Q1 200 53.0 M $6.83 B
2020 Q4 193 54.4 M $9.07 B
2020 Q3 166 53.6 M $8.27 B
2020 Q2 168 48.3 M $7.14 B
2020 Q1 159 48.4 M $5.45 B
2019 Q4 154 46.2 M $6.42 B
2019 Q3 137 46.1 M $4.44 B
2019 Q2 149 47.8 M $5.50 B
2019 Q1 164 47.2 M $5.55 B
2018 Q4 114 40.1 M $2.51 B
2018 Q3 107 41.0 M $2.90 B
2018 Q2 111 42.2 M $2.80 B
2018 Q1 93 38.2 M $2.50 B
2017 Q4 65 30.5 M $1.22 B
2017 Q3 60 28.8 M $1.04 B
2017 Q2 35 23.3 M $646 M
2017 Q1 36 20.9 M $585 M
2016 Q4 32 20.6 M $416 M
2016 Q3 22 14.0 M $281 M
2016 Q2 23 13.9 M $184 M
2016 Q1 26 12.0 M $223 M
2015 Q4 25 10.1 M $185 M
2015 Q3 27 9.68 M $177 M
2015 Q2 33 8.95 M $158 M
2015 Q1 36 8.48 M $146 M